In addition, FDA’s neuroscience chief Billy Dunn, who had a hand in the approval of the previous Duchenne drugs, left the regulatory agency at the end of February. The first Duchenne treatment, Sarepta’s Exondys 51, was approved by the FDA after an advisory committee voted against it.
ANP Price at posting:
8.7¢ Sentiment: Buy Disclosure: Held
